Novo Nordisk A/S (NYSE:NVO) saw a downside of -0.84% to close Tuesday at $139.90 after subtracting -$1.18 on the day. The 5-day average trading volume is 1,757,800 shares of the company’s common stock. It has gained $144.78 in the past week and touched a new high 4 times within the past 5 days. An average of 1,441,485 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,368,148.
NVO’s 1-month performance is 5.59% or $5.90 on its low of $130.10 reached on 01/12/23. The company’s shares have touched a 52-week low of $91.51 and high of $141.50, with the stock’s rally to the 52-week high happening on 01/24/23. YTD, NVO has achieved 3.37% or $4.56 and has reached a new high 9 times. However, the current price is down -1.13% from the 52-week high price.
NVO stock has a beta of 0.50. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 9.87 while the price-to-book (PB) in the most recent quarter is 28.32, with the price to cash flow ratio at 48.19.
Novo Nordisk A/S’s quick ratio for the period ended June 29 was 0.70, with the current ratio over the same period at 0.90. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.31, while the total debt to equity was 0.34.. In terms of profitability, the gross margin trailing 12 months is 84.20%. The trailing 12-month EBITDA margin is 45.68% while for the period ending June 29, Novo Nordisk A/S’s operating margin was 42.70%. The firm’s gross profit as reported stood at $18.64 billion against revenue of $22.4 billion.
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected NVO to announce $0.74 per share in earnings in its latest quarter, but it posted $0.78, representing a 5.40% surprise. EBITDA for the quarter stood at more than $2.98 billion. NVO stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 22.48 billion, with total debt at $25.43 billion.
Let’s look briefly at Novo Nordisk A/S (NVO) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 63.90% to suggest the stock is trending Neutral, with historical volatility in this time period at 14.59%.
The stock’s 5-day moving average is $140.50, reflecting a +0.66% or $0.92 change from its current price. NVO is currently trading +4.70% above its 20-day SMA, +31.93% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +22.54% and SMA200 by+19.44%.
Stochastic %K and %D was 87.66% and 93.64% and the average true range (ATR) pointed at 2.64. The RSI (14) points at 65.38%, while the 14-day stochastic is at 66.76% with the period’s ATR at 2.53. The stock’s 9-day MACD Oscillator is pointing at 2.47 and 3.08 on the 14-day charts.
In the most recent analyst report for Novo Nordisk A/S (NYSE: NVO), Morgan Stanley upgraded it to an Overweight rating. They previously had an Equal-weight rating on the stock. Analysts offering their rating for NVO stock have a consensus rating for the stock as Overweight. Currently, 3 brokerage advisors rate NVO as a “sell,”, while 7 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 2 rates the stock as overweight while 14 have offered a “buy” rating.
What is NVO’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $75.50 and a high of $174.72, with their median price target at $144.86. Looking at these predictions, the average price target given by analysts is for Novo Nordisk A/S (NVO) stock is $137.52.